Cajal Neuroscience

Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.

Cajal Neuroscience headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Therapeutics, Neuroscience sector. The company focuses on Biotechnology and has secured $3.1B in funding across 32 round(s). With a team of 51-100 employees, Cajal Neuroscience is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cajal Neuroscience, raised $96.0M. Discover more about their projects, partnerships, and impact on our platform.